2015
A Randomized Trial for Hazardous Drinking and Smoking Cessation for Callers to a Quitline
Toll BA, Martino S, O’Malley S, Fucito LM, McKee SA, Kahler CW, Rojewski AM, Mahoney MC, Wu R, Celestino P, Seshadri S, Koutsky J, Hyland A, Cummings KM. A Randomized Trial for Hazardous Drinking and Smoking Cessation for Callers to a Quitline. Journal Of Consulting And Clinical Psychology 2015, 83: 445-454. PMID: 25419583, PMCID: PMC5996380, DOI: 10.1037/a0038183.Peer-Reviewed Original ResearchConceptsStandard careHazardous drinkingHigher smoking cessation ratesNew York State Smokers' QuitlineHeavy drinkingBrief motivational counselingSmoking cessation ratesState Smokers' QuitlineBrief alcohol interventionTelephone coachesCessation counselingTreat analysisCessation ratesRandomized trialsTelephone quitlinesCessation successSmoking cessationAcceptable adherenceMotivational counselingQuitlineAlcohol interventionsAlcohol useCareSmokersDrinking
2006
A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation
O’Malley S, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P. A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation. JAMA Internal Medicine 2006, 166: 667-674. PMID: 16567607, DOI: 10.1001/archinte.166.6.667.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAmbulatory CareDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHumansLinear ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsNicotineNicotinic AgonistsSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTreatment OutcomeWeight GainConceptsNicotine patch therapyNicotine patchPatch therapyDouble-blind placebo-controlled trialHigher continuous abstinence ratesLow-dose naltrexone therapyNaltrexone hydrochlorideWeight gainTreatment completersOral naltrexone hydrochlorideOutpatient research centerWeight-concerned smokersContinuous abstinence ratesPlacebo-controlled trialPrimary end pointSecond-line treatmentNicotine replacement therapyNaltrexone augmentationNaltrexone therapyPlacebo groupQuit dateTreat analysisAbstinence ratesReplacement therapySmoking cessation